Selin Kurnaz: Massive Bio and Precision Cancer Consortium’s collaborative abstract accepted at ASCO24

Selin Kurnaz, Co-Founder and CEO at Massive Bio, shared on LinkedIn:

“I am beyond proud to announce that Massive Bio and Precision Cancer Consortium’s collaborative abstract accepted at American Society of Clinical Oncology (ASCO) 2024.

Our abstract is called ‘Effect of a novel artificial intelligence (AI) –enabled multi-trial matching system on patient matching using real-world data’. .

This is the first time this level of large patient cohort (5,707 cancer patients) is analyzed in the context of AI-based clinical trial matching.

I would like to send special thanks to our collaborators AstraZeneca, Bayer Pharmaceuticals, Eli Lilly and Company, GSK, Johnson and Johnson, Novartis and Roche.

And further my partners, Arturo LoAIza-Bonilla, Çağatay M. Çulcuoğlu and my rockstar team and volunteers that believe in our mission, Oz Huner, Dersu Giritlioglu and Darla Carvallo.

We put countless hours and sweat on to this work, but we are exceptionally proud to move and shake the industry and show people that impossible is infact possible.

We also invite all ASCO2024 participants to our booth #29137 to see live demonstration on Massive Bio’s cutting-edge products and further see our poster. Please come and join us.”

Source: Selin Kurnaz/LinkedIn